Pharvaris (PHVS)
(Real Time Quote from BATS)
$20.78 USD
+1.23 (6.29%)
Updated May 24, 2024 11:54 AM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
PHVS 20.78 +1.23(6.29%)
Will PHVS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PHVS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PHVS
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program
PHVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
Wall Street Analysts Predict an 88.24% Upside in Pharvaris N.V. (PHVS): Here's What You Should Know
Other News for PHVS
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
Pharvaris’s Promising Drug Candidate Deucrictibant Bolsters Buy Rating
Analysts Are Bullish on Top Healthcare Stocks: Steris (STE), Pharvaris (PHVS)
Pharvaris reports Q1 results
Pharvaris price target lowered by $4 at Wedbush, here's why